 use sku level databas million record track
approxim mdt us revenu point via sku
compani
 point data februari march plan updat
tracker april data earli next week
 crhf us sale look slight miss csh slight beat
spine slight miss brain therapi slight beat
specialti therapi slight miss net-net reduc
revenu estim leav ep unchang
penni consensu
guidanc creat bridg ep highlight
area potenti upsid tax save estim
headwind china tariff impact dcb net-net
believ ep could bracket street pleas see note
 believ eye move piec within mdt portfolio
oper leverag bull side investor focus mdt
pipelin question need buy ahead key product
introduct like surgic robot tmvr bear side investor
question whether defend diabet franchis note
upsid pipelin isnt within next quarter
price may usd
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
alway lot move part tri focu one realli move needl
biggest uncertainti us model relat
achiev margin leverag
much tax save achiev
extent dcb pressur
segment track far
use db sku level databas line data correspond sku track
data predict mdt divis repres mdt us revenu global revenu
continu updat model expect abl track divis except diabet within next quarter
usoustot revenuescardiac vascular groupcardiac rhythm heart coronari structur aortic peripher restor therapi brain specialti pain minim invas therapi groupsurg respiratori gi total percent us revenu total revenu revenu model chang
month data far
point data februari march get april data next week
ahead mdt earn make adjust model base data hand
ultim adjust minor put take revenu declin
ep estim remain unchang versu consensu guidanc
db consensussal mm cardiac rhythm heart structur peripher group group innov surgic gi renal patient monitor group group consolid cardiac rhythm heart failur total us sale
model y/i declin slight improv declin
db proprietari dataset signal less steadi crhf growth trend sequenti
continu share gain bradi driven micra leadless pacer azur
persist sluggish tachi thank larg continu replac cycl headwind crt
structur competit pressur lvad corrobor abt commentari substanti share gain versu hvad
coronari structur heart total us sale
model growth slight improv growth
db proprietari dataset signal decent sequenti growth deceler
evolut continu yield above-market us tavr growth
potenti tavr market acceler late post low-risk data howev yet sale figur april data
would captur initi april data expect next week
cardiac vascular group area focu
report continu weak high- low-voltag note continu weak pacer albeit sequenti improv
continu momentum icd due emblem resonate/heartlog offer
consist commentari competitor forese continu bradi share captur driven proprietari micra leadless pacer azur continu tachi
share loss continu saw prior quarter
follow posit wrap-it data look updat commentari around tyrx includ expect around potenti guidelin chang continu think
tyrx could yield potenti meaning share captur
note strong growth continu share captur impli continu pressur hvad declin estim
lvad share captur
look latest commentari around impact us guidelin chang
ew estim us ou procedur grew ldd believ ww sapien share drop modestli yr/yr global flat sequenti impli
yr/yr share gain corevalv global jibe data
commentari around initi impact low-risk data tavr volum interest
attribut growth deceler us growth af franchis time product launch fundament slowdown market
corrobor continu strength jnj biosens webster busi
look continu double-digit growth cryoablat
despit safeti concern around paclitaxel-elut devic pact growth nonetheless healthi howev subsequ fda physician advisori march
may yield effect util suggest result commentari lutonix dcb fda advisori saw substanti
declin dcb sale presum impact magnitud remaind year
accordingli apv estim may come saw similar hit pact util back half
updat key cvg pipelin program
tavr latest time eu launch next-gen evolut
mitral apollo enrol updat progress/tim transsept deliver iter intrepid valv
cardiac vascular groupfi rhythm heart failurerevenuesunit yr/yr unit constant constant structur heartrevenuesunit yr/yr unit constant constant peripher vascularrevenuesunit yr/yr unit constant constant group totalrevenuesunit yr/yr unit constant constant spine total us sale
model declin step-down versu declin
db proprietari dataset signal rel stabl trend sequenti core spine
consist competitor result
expect mazor benefit mdt core spine implant growth/shar appear yet manifest meaning way
acknowledg increment implant price pressur commentari thu interest
brain therapi total us sale
model grow step-down versu growth
db proprietari dataset signal potenti meaning growth deceler
comp brain therapi much tougher may partial explain slowdown
post healthi double-digit us neurovascular growth continu roll-out surpass may start imping
mdt flow divert perform though unlik meaning way point clinician train continu measur pace
note brain therapi sale data captur capit equip sale mazor stealthstat o-arm
specialti therapi total us sale
model declin step-down versu growth
db proprietari dataset signal potenti meaning growth deceler
steadi growth ent
continu faster growth transform solut product like aquamani bipolar sealer
restor therapi group area focu
sustain growth high teen recent quarter stent retriev flow divert access embol product grow doubl digit late
competit landscap light multipl new launch includ syk surpass flow divert fda approv juli impact surpass like
substanti given syk commentari pace surpass launch measur consist recent us sale data point de minimu
sustain strong recent momentum capit equip stealthstat navig o-arm imag mazor robot sale particularli on-going launch mazor
result competitor suggest rel steadi market dynam acknowledg increment price pressur whether market leader
also observ interest
light aforement strength neurosurgeri capit equip if/when begin effect meaning benefit core spine implant growth
continu expect also interest
market growth share trend light increasingli competit market
market growth remain hotli debat topic among investor particularli given even manufactur estim wide-rang
abt growth expect though manag attribut company-specif factor continu see double-digit grower
also under-perform post double-digit growth
intelli sale close watch continu uptak new system remain critic share recaptur
updat key rtg pipelin program
next-gen interstim time particularli import given axnx upcom entri sn market
initi sale trend multipl neurovascular devic recent launch includ react cathet riptid aspir platform next-gen solitair
restor therapi groupfi yr/yr unit constant constant therapiesrevenuesunit yr/yr unit constant constant therapiesrevenuesunit yr/yr unit constant constant therapiesrevenuesunit yr/yr unit constant constant group totalrevenuesunit yr/yr unit constant constant minim invas therapi group area focu db segment
manag updat critic pipelin program biggest area spend past sever year top area focu
expect initi commerci placement reiter call investor would react posit timelin kept intact next week call
expect around placements/growth contribut beyond huge interest street
growth remain strong ldd hsd respect fuel new product tristapl reload continu growth penetr
result commentari suggest continu good perform busi mdt
up invest target new growth opportun like minim invas gi diagnostics/therapeut extent yield better division
growth come quarter remain area investor focu
minim invas therapi groupfi innov surgic solut revenuesunit yr/yr unit constant constant gi renal patient monitor recoveri revenuesunit yr/yr unit constant constant group totalrevenuesunit yr/yr unit constant constant diabet group area focu db segment revenu build
among one mdt import new product introduct adopt trend thu remain key metric interest
cgm grew look continu momentum beyond includ recent launch guardian connect stand-alone
cgm grown tripl digit prior three quarter
report robust sale growth freestyl libr cgm system
boost focus/invest space compani current compet henc inroad could prove meaning growth
updat key diabet group pipelin program
next-gen cgm system previou guidanc launch time guardian sensor non-inject segment
tndm robust growth could come mdt expens given lead market share product cycl dynam
tariff potenti market slow
know
prior recent round tariff disclos dilut
mzor china tariff combin headwind
use fill assumpt around sg leverag believ
mzor acquisit dilut mdt guidanc
henc estim tariff guidanc
know revenu china assum
china rev grew estim revenu
china
annual estim annual run-rat
rev lost tariff mdt china revenu
project china growth slow model revenu
china
assum tariff doubl believ impact
could
note us china trade issu highli fluid chang
sg tax day deal close estim estim revenu estimate ep hit annual impli revenu rev estim revenu rev revenu revenu ep tax
guid tax increas begin competitor confer earli januari
wrote believ major increas came hybrid tax loophol close
specif compani loan money countri like luxemburg us would creat tax shield us howev
luxemburg view inter-company loan dividend werent tax allow quit bit tax save zero off-set
provid updat tax guidanc week time loophol close disclosur
